Skip to main content
OpenTrials
Completed

NCT Number: NCT03071679

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

This study has a randomized, evaluator-blinded, vehicle- controlled study to assess the pharmacodynamics of omiganan and omiganan with imiquimod in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

LUMC/Centre for Human Drug Research

Leiden, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, blood serology and urinalysis.
  • Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum weight of 50 kg.
  • Fitzpatrick skin type I-III (Caucasian)
  • Subjects and their partners of childbearing potential must use effective contraception, for the duration of the study and for 3 months after the last dose.
  • Able and willing to give written informed consent and to comply with the study restrictions.

Exclusion criteria

  • Any disease associated with immune system impairment, including auto-immune diseases, HIV and transplantation patients
  • Family history of psoriasis
  • History of pathological scar formation (keloid, hypertrophic scar)
  • Have any current and / or recurrent pathologically, clinical significant skin condition.
  • Previous use of imiquimod/ resiquimod/ gardiquimod
  • Known hypersensitivity to the (non)investigational drug, drugs of the same class, or any of their excipients.
  • Hypersensitivity for dermatological marker at screening
  • Requirement of immunosuppressive or immunomodulatory medication within 30 days prior to enrollment or planned to use during the course of the study.
  • Use of topical medication (prescription or over-the-counter [OTC]) within 30 days of study drug administration, or less than 5 half-lives (whichever is longer) in local treatment area
  • Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment.
  • Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.
  • Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening
  • Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding

Treatment and study plan

Omiganan

Drug

Omignan 1%, 2.5%

Imiquimod

Drug

Imiquimod 15mg

Omiganan 1% and Imiquimod

Drug

Omiganan 1% and Imiquimod

Omiganan 2.5% and Imiquimod

Drug

Omiganan 2.5% and Imiquimod

Placebo

Drug

Vehicle

Primary outcomes

  1. Clinical Evaluation

    Time frame: 6 Days

    Erythema grading scale

  2. Pharmacodynamic (Biomarkers)

    Time frame: Within 2 Weeks

    Local biomarker sequencing

  3. Pharmacodynamic (Histology)

    Time frame: Within 2 Weeks

    Histological parameters assessment

  4. Pharmacodynamic (Immunohistochemistry)

    Time frame: Within 2 Weeks

    Identification of lymphocytes and lineage cells

  5. Pharmacodynamic (TAP)

    Time frame: Within 6 Days

    Qualitatively and Quantitatively analyze biomarkers captured by Trans Epidermal Patch (TAP)

  6. pharmacodynamic (LSCI)

    Time frame: Within 6 Days

    Assess cutaneous microcirculation using laster speckle imager

  7. Pharmacodynamic (Colorimetry)

    Time frame: Within 6 Days

    Colorimetric assessment by erythema grading scale

  8. Pharmacodynamic (Photography)

    Time frame: Within 2 Weeks

    Photographs of treatment sites will be taken

  9. Pharmacodynamic (Thermography)

    Time frame: Within 2 Weeks

    Skin temperature measurements will be taken

Secondary outcomes

  1. Local tolerability

    Time frame: 2 Weeks

    Visual Analogue Scale (NRS) pruritus and pain

  2. Safety (AE)

    Time frame: 2 Weeks

    Adverse Events will be collected throughout the study

  3. Safety (Vital Signs)

    Time frame: 2 Weeks

    Vital Signs will be collected throughout the study

  4. Safety (Laboratory Safety Testing)

    Time frame: 2 Weeks

    Lab samples collected in various timepoints within the study

  5. Safety (ECG)

    Time frame: Within 3 Weeks

    ECGs will be collected before beginning and end of study

Sponsors and collaborators

Lead sponsor

Maruho Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Evaluator-blinded, Vehicle-controlled Study to Explore the Pharmacodynamic Effects of Omiganan and Omiganan in Combination With Imiquimod in Healthy Volunteers

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Mar 7, 2017
Registry last updated
May 22, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.